The utility of immunostaining for NUT, GAGE7 and NY-ESO-1 in the diagnosis of spermatocytic seminoma

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Aims: To identify specific positive immunohistochemical markers for spermatocytic seminoma (SS). Methods and results: We studied the reactivity of 94 (total) cases of SS, seminoma, embryonal carcinoma and solid yolk sac tumour with antibodies against nuclear protein in testis (NUT) and two cancer/testis antigens, GAGE7 and NY-ESO-1. When tumour positivity was defined as an extent plus intensity score of ≥4, NUT was positive in 71% of SSs, 19% of seminomas, and 5% of solid yolk sac tumours. GAGE7 was positive in 67% of SSs and 4% of seminomas. NY-ESO-1 was positive in 82% of SSs, 13% of seminomas, and 5% of solid yolk sac tumours. The sensitivity and specificity, respectively, of these antibodies for SSs were as follows: NUT, 71% and 92%; GAGE7, 67% and 99%; and NY-ESO-1, 82% and 94%. When positivity criteria were stricter, NUT and GAGE7 positivity occurred exclusively in SS, but the sensitivity decreased to 41% and 60%, respectively, and NY-ESO-1 was 59% sensitive and 97% specific. Neither the sarcomatous component of three SSs nor any embryonal carcinoma showed reactivity with any antibody. Conclusions: All three antibodies are variably sensitive for SS, and high specificity is attained when there is multifocal and strong nuclear labelling.

Original languageEnglish
Pages (from-to)35-44
Number of pages10
JournalHistopathology
Volume65
Issue number1
DOIs
StatePublished - 2014

Fingerprint

Seminoma
Nuclear Proteins
Testis
Endodermal Sinus Tumor
Embryonal Carcinoma
Testicular Neoplasms
Antibodies
Neoplasm Antibodies
Antigens
Sensitivity and Specificity

Keywords

  • Cancer/testis antigens
  • Germ cell tumour
  • Immunohistochemistry
  • NUT
  • Spermatocytic seminoma
  • Testicular neoplasms

ASJC Scopus subject areas

  • Histology
  • Pathology and Forensic Medicine
  • Medicine(all)

Cite this

The utility of immunostaining for NUT, GAGE7 and NY-ESO-1 in the diagnosis of spermatocytic seminoma. / Kao, Chia Sui; Badve, Sunil; Ulbright, Thomas.

In: Histopathology, Vol. 65, No. 1, 2014, p. 35-44.

Research output: Contribution to journalArticle

@article{424b57e7880743edb88d46429aaa3a6d,
title = "The utility of immunostaining for NUT, GAGE7 and NY-ESO-1 in the diagnosis of spermatocytic seminoma",
abstract = "Aims: To identify specific positive immunohistochemical markers for spermatocytic seminoma (SS). Methods and results: We studied the reactivity of 94 (total) cases of SS, seminoma, embryonal carcinoma and solid yolk sac tumour with antibodies against nuclear protein in testis (NUT) and two cancer/testis antigens, GAGE7 and NY-ESO-1. When tumour positivity was defined as an extent plus intensity score of ≥4, NUT was positive in 71{\%} of SSs, 19{\%} of seminomas, and 5{\%} of solid yolk sac tumours. GAGE7 was positive in 67{\%} of SSs and 4{\%} of seminomas. NY-ESO-1 was positive in 82{\%} of SSs, 13{\%} of seminomas, and 5{\%} of solid yolk sac tumours. The sensitivity and specificity, respectively, of these antibodies for SSs were as follows: NUT, 71{\%} and 92{\%}; GAGE7, 67{\%} and 99{\%}; and NY-ESO-1, 82{\%} and 94{\%}. When positivity criteria were stricter, NUT and GAGE7 positivity occurred exclusively in SS, but the sensitivity decreased to 41{\%} and 60{\%}, respectively, and NY-ESO-1 was 59{\%} sensitive and 97{\%} specific. Neither the sarcomatous component of three SSs nor any embryonal carcinoma showed reactivity with any antibody. Conclusions: All three antibodies are variably sensitive for SS, and high specificity is attained when there is multifocal and strong nuclear labelling.",
keywords = "Cancer/testis antigens, Germ cell tumour, Immunohistochemistry, NUT, Spermatocytic seminoma, Testicular neoplasms",
author = "Kao, {Chia Sui} and Sunil Badve and Thomas Ulbright",
year = "2014",
doi = "10.1111/his.12365",
language = "English",
volume = "65",
pages = "35--44",
journal = "Histopathology",
issn = "0309-0167",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - The utility of immunostaining for NUT, GAGE7 and NY-ESO-1 in the diagnosis of spermatocytic seminoma

AU - Kao, Chia Sui

AU - Badve, Sunil

AU - Ulbright, Thomas

PY - 2014

Y1 - 2014

N2 - Aims: To identify specific positive immunohistochemical markers for spermatocytic seminoma (SS). Methods and results: We studied the reactivity of 94 (total) cases of SS, seminoma, embryonal carcinoma and solid yolk sac tumour with antibodies against nuclear protein in testis (NUT) and two cancer/testis antigens, GAGE7 and NY-ESO-1. When tumour positivity was defined as an extent plus intensity score of ≥4, NUT was positive in 71% of SSs, 19% of seminomas, and 5% of solid yolk sac tumours. GAGE7 was positive in 67% of SSs and 4% of seminomas. NY-ESO-1 was positive in 82% of SSs, 13% of seminomas, and 5% of solid yolk sac tumours. The sensitivity and specificity, respectively, of these antibodies for SSs were as follows: NUT, 71% and 92%; GAGE7, 67% and 99%; and NY-ESO-1, 82% and 94%. When positivity criteria were stricter, NUT and GAGE7 positivity occurred exclusively in SS, but the sensitivity decreased to 41% and 60%, respectively, and NY-ESO-1 was 59% sensitive and 97% specific. Neither the sarcomatous component of three SSs nor any embryonal carcinoma showed reactivity with any antibody. Conclusions: All three antibodies are variably sensitive for SS, and high specificity is attained when there is multifocal and strong nuclear labelling.

AB - Aims: To identify specific positive immunohistochemical markers for spermatocytic seminoma (SS). Methods and results: We studied the reactivity of 94 (total) cases of SS, seminoma, embryonal carcinoma and solid yolk sac tumour with antibodies against nuclear protein in testis (NUT) and two cancer/testis antigens, GAGE7 and NY-ESO-1. When tumour positivity was defined as an extent plus intensity score of ≥4, NUT was positive in 71% of SSs, 19% of seminomas, and 5% of solid yolk sac tumours. GAGE7 was positive in 67% of SSs and 4% of seminomas. NY-ESO-1 was positive in 82% of SSs, 13% of seminomas, and 5% of solid yolk sac tumours. The sensitivity and specificity, respectively, of these antibodies for SSs were as follows: NUT, 71% and 92%; GAGE7, 67% and 99%; and NY-ESO-1, 82% and 94%. When positivity criteria were stricter, NUT and GAGE7 positivity occurred exclusively in SS, but the sensitivity decreased to 41% and 60%, respectively, and NY-ESO-1 was 59% sensitive and 97% specific. Neither the sarcomatous component of three SSs nor any embryonal carcinoma showed reactivity with any antibody. Conclusions: All three antibodies are variably sensitive for SS, and high specificity is attained when there is multifocal and strong nuclear labelling.

KW - Cancer/testis antigens

KW - Germ cell tumour

KW - Immunohistochemistry

KW - NUT

KW - Spermatocytic seminoma

KW - Testicular neoplasms

UR - http://www.scopus.com/inward/record.url?scp=84902072724&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902072724&partnerID=8YFLogxK

U2 - 10.1111/his.12365

DO - 10.1111/his.12365

M3 - Article

C2 - 24393139

AN - SCOPUS:84902072724

VL - 65

SP - 35

EP - 44

JO - Histopathology

JF - Histopathology

SN - 0309-0167

IS - 1

ER -